Current and historical daily PE Ratio for PBYI (
Puma Biotechnology Inc
) from 2012 to Apr 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Puma Biotechnology stock (PBYI) PE ratio as of Apr 28 2024 is 11.16.
More Details
Puma Biotechnology Inc (PBYI) PE Ratio (TTM) Chart
Puma Biotechnology Inc (PBYI) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Puma Biotechnology PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-28 | 11.2 | 2024-02-23 | 14.6 |
| 2024-04-26 | 11.2 | 2024-02-22 | 13.1 |
| 2024-04-25 | 10.8 | 2024-02-21 | 14.5 |
| 2024-04-24 | 10.7 | 2024-02-20 | 15.1 |
| 2024-04-23 | 11.4 | 2024-02-16 | 15.8 |
| 2024-04-22 | 11.5 | 2024-02-15 | 15.5 |
| 2024-04-19 | 11.1 | 2024-02-14 | 16.4 |
| 2024-04-18 | 11.1 | 2024-02-13 | 13.8 |
| 2024-04-17 | 11.5 | 2024-02-12 | 14.1 |
| 2024-04-16 | 11.3 | 2024-02-09 | 12.8 |
| 2024-04-15 | 11.9 | 2024-02-08 | 12.0 |
| 2024-04-12 | 11.7 | 2024-02-07 | 11.2 |
| 2024-04-11 | 12.2 | 2024-02-06 | 11.2 |
| 2024-04-10 | 12.3 | 2024-02-05 | 10.8 |
| 2024-04-09 | 13.0 | 2024-02-02 | 10.5 |
| 2024-04-08 | 12.5 | 2024-02-01 | 10.9 |
| 2024-04-05 | 12.6 | 2024-01-31 | 10.4 |
| 2024-04-04 | 12.2 | 2024-01-30 | 10.6 |
| 2024-04-03 | 11.9 | 2024-01-29 | 11.1 |
| 2024-04-02 | 11.7 | 2024-01-26 | 10.8 |
| 2024-04-01 | 11.7 | 2024-01-25 | 11.0 |
| 2024-03-28 | 11.8 | 2024-01-24 | 11.1 |
| 2024-03-27 | 12.4 | 2024-01-23 | 11.1 |
| 2024-03-26 | 12.4 | 2024-01-22 | 11.1 |
| 2024-03-25 | 12.4 | 2024-01-19 | 10.5 |
| 2024-03-22 | 11.8 | 2024-01-18 | 11.4 |
| 2024-03-21 | 11.9 | 2024-01-17 | 11.1 |
| 2024-03-20 | 10.4 | 2024-01-16 | 12.1 |
| 2024-03-19 | 9.6 | 2024-01-12 | 11.0 |
| 2024-03-18 | 10.4 | 2024-01-11 | 10.1 |
| 2024-03-15 | 11.1 | 2024-01-10 | 10.6 |
| 2024-03-14 | 11.6 | 2024-01-09 | 10.6 |
| 2024-03-13 | 11.8 | 2024-01-08 | 10.7 |
| 2024-03-12 | 11.9 | 2024-01-05 | 10.4 |
| 2024-03-11 | 12.2 | 2024-01-04 | 9.5 |
| 2024-03-08 | 11.9 | 2024-01-03 | 9.8 |
| 2024-03-07 | 12.8 | 2024-01-02 | 10.1 |
| 2024-03-06 | 12.3 | 2023-12-29 | 9.6 |
| 2024-03-05 | 11.5 | 2023-12-28 | 9.7 |
| 2024-03-04 | 11.9 | 2023-12-27 | 54.3 |
| 2024-03-01 | 13.1 | 2023-12-26 | 55.8 |
| 2024-02-29 | 13.8 | 2023-12-22 | 51.5 |
| 2024-02-28 | 14.7 | 2023-12-21 | 49.3 |
| 2024-02-27 | 14.4 | 2023-12-20 | 49.1 |
| 2024-02-26 | 14.4 | 2023-12-19 | 50.0 |
Puma Biotechnology Inc (PBYI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Puma Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US74587V1070
Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers